Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
A CCR2+ myeloid cell niche required for pancreatic β cell growth
Kristin Mussar, … , Vincenzo Cirulli, Laura Crisa
Kristin Mussar, … , Vincenzo Cirulli, Laura Crisa
Published August 3, 2017
Citation Information: JCI Insight. 2017;2(15):e93834. https://doi.org/10.1172/jci.insight.93834.
View: Text | PDF
Research Article Development Endocrinology

A CCR2+ myeloid cell niche required for pancreatic β cell growth

  • Text
  • PDF
Abstract

Organ-specific patterns of myeloid cells may contribute tissue-specific growth and/or regenerative potentials. The perinatal stage of pancreas development marks a time characterized by maximal proliferation of pancreatic islets, ensuring the maintenance of glucose homeostasis throughout life. Ontogenically distinct CX3CR1+ and CCR2+ macrophage populations have been reported in the adult pancreas, but their functional contribution to islet cell growth at birth remains unknown. Here, we uncovered a temporally restricted requirement for CCR2+ myeloid cells in the perinatal proliferation of the endocrine pancreatic epithelium. CCR2+ macrophages are transiently enriched over CX3CR1+ subsets in the neonatal pancreas through both local expansion and recruitment of immature precursors. Using CCR2-specific depletion models, we show that loss of this myeloid population leads to a striking reduction in β cell proliferation, dysfunctional islet phenotypes, and glucose intolerance in newborns. Replenishment of pancreatic CCR2+ myeloid compartments by adoptive transfer rescues these defects. Gene profiling identifies pancreatic CCR2+ myeloid cells as a prominent source of IGF2, which contributes to IGF1R-mediated islet proliferation. These findings uncover proproliferative functions of CCR2+ myeloid subsets and identify myeloid-dependent regulation of IGF signaling as a local cue supporting pancreatic proliferation.

Authors

Kristin Mussar, Stephanie Pardike, Tobias M. Hohl, Gary Hardiman, Vincenzo Cirulli, Laura Crisa

×

Figure 6

Effects of CCR2+ cell depletion on the proliferation of the exocrine and endocrine compartments of the pancreas.

Options: View larger image (or click on image) Download as PowerPoint
Effects of CCR2+ cell depletion on the proliferation of the exocrine and...
(A) Pancreatic sections of diphtheria toxin–treated (DT-treated) P10 mice stained for amylase, insulin and the proliferation marker PCNA. Scale bar: 50 μm. Representative of at least n = 4 per group. (B and C) Frequency of PCNA+ cells detected within amylase+ (B) and insulin+ (C) areas. (D and E) Morphometric analysis of amylase+ and insulin+ areas. (F) Frequency of TUNEL+ apoptotic cells in pancreatic epithelial tissue identified by E-cadherin staining. (B–F) Mean ± SEM of n = 3–4 mice per group. (G) Frequency of proliferating epithelial cells in P2 pancreatic explants from CCR2DTR/+ mice and WT littermates after culture in the presence or absence of DT (n = 2–4 experiments using pools of 3–4 pancreata). (H) PCR analysis of CCR2 and CD11b mRNA transcripts in organ cultures shown in G, validating the depletion of CCR2+ cells in DT-treated CCR2DTR/+ tissues. Mean + SD. Representative of n = 2–4 experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA nonparametric test, followed by Bonferroni post-hoc test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts